Mawer Investment Management Ltd. trimmed its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 16.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 361,477 shares of the company’s stock after selling 69,769 shares during the quarter. Mawer Investment Management Ltd.’s holdings in AbbVie were worth $94,559,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. State Street Corp grew its holdings in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. Fisher Asset Management LLC increased its position in AbbVie by 252.6% during the 3rd quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after purchasing an additional 23,991,451 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Legal & General Group Plc purchased a new position in AbbVie in the second quarter valued at approximately $2,905,952,000. Finally, Deutsche Bank AG raised its holdings in AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after buying an additional 1,241,587 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
AbbVie Stock Up 0.2%
Shares of NYSE ABBV traded up $0.73 on Friday, hitting $295.18. The company had a trading volume of 3,259,920 shares, compared to its average volume of 5,279,493. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $302.93. The firm has a market capitalization of $521.76 billion, a P/E ratio of 50.81, a PEG ratio of 1.34 and a beta of 0.20. The business has a 50 day moving average of $275.51 and a two-hundred day moving average of $240.91.
AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $1.86 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.
AbbVie Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $1.82 dividend. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio (DPR) is currently 125.30%.
Latest AbbVie News
Here’s some of the latest news about ABBV:
- Positive Sentiment: AbbVie reported positive Phase 3 results for QULIPTA in a migraine trial, a potential boost to its neuroscience portfolio and the drug’s growth prospects. AbbVie Reports Positive Phase 3 QULIPTA Migraine Trial Results
- Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
- Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock
Analysts Set New Price Targets
A number of brokerages have weighed in on ABBV. Piper Sandler lifted their price target on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. Scotiabank increased their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Wells Fargo & Company raised their target price on shares of AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Finally, Rothschild & Co Redburn lifted their target price on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $297.46.
View Our Latest Report on ABBV
Insider Transactions at AbbVie
In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This trade represents a 32.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by company insiders.
AbbVie Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Further Reading
- Five stocks we like better than AbbVie
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
